Caplacizumab: TMA Camila Masias ASH 2022 Complement-Mediated HRES Debate By Camila Masias, MD How will Caplacizumab help patients with TMAs?…
Browsing: leukemia
iFrame is not supported! Notable Labs: Thomas Bock ASH 2022 The Future of AML Treatment By Thomas Bock, MD, MBA…
Notable Labs: Thomas Bock ASH 2022 The Future of AML Treatment By Thomas Bock, MD, MBA Where is the blood…
iFrame is not supported! VERIFY Trial PV: ASH 2022 Phase 3 Study on PTG-300 Srdan Verstovsek By Srdan Verstovsek, MD,…
VERIFY Trial PV: ASH 2022 Phase 3 Study on PTG-300 Srdan Verstovsek By Srdan Verstovsek, MD, PhD How will the…
iFrame is not supported! Idecabtagene: ASH 2022 Multiple Myeloma Madhav Dhodapkar KarMMa-2 By Madhav Dhodapkar, MBBS What is Idecabtagene, and…
Idecabtagene: ASH 2022 Multiple Myeloma Madhav Dhodapkar KarMMa-2 By Madhav Dhodapkar, MBBS What is Idecabtagene, and how can it help…
iFrame is not supported! Isatuximab: ASH 2022 Multiple Myeloma Paul Richardson ICARIA By Paul Richardson, MD What can Pomalidomide/Dexamethasone do…
Isatuximab: ASH 2022 Multiple Myeloma Paul Richardson ICARIA By Paul Richardson, MD What can Pomalidomide/Dexamethasone do for Relapsed/Refractory Multiple Myeloma…
Zanubrutinib: Superior PFS in CLL Jennifer Brown, MD – ASH 2022 By Jennifer Brown, MD I’ll be discussing the alpine…
iFrame is not supported! Pacritinib: Phase 3 PACIFICA Trial Dr. Mascarenhas ASH 2022 By John Mascarenhas, MD What is the…
Pacritinib: Phase 3 PACIFICA Trial Dr. Mascarenhas ASH 2022 By John Mascarenhas, MD What is the study of Pacritinib in…
iFrame is not supported! Dasatinib or Imatinib: Final 5-Year Results From DASCERN Dr. Cortes ASH 2022 By Jorge Cortes, MD…
Dasatinib or Imatinib: Final 5-Year Results From DASCERN Dr. Cortes ASH 2022 By Jorge Cortes, MD What is the DASCERN…
iFrame is not supported! Momelotinib: Update On MOMENTUM Trial Dr. Gerds ASH 2022 By Aaron Gerds, MD What is the…
Momelotinib: Update On MOMENTUM Trial Dr. Gerds ASH 2022 By Aaron Gerds, MD What is the difference between the Momelotinib…
iFrame is not supported! Axicabtagene Ciloleucel (Axi-Cel) Large B-Cell Lymphoma (R/R LBCL): 2-Year Follow-up of ZUMA-1 Cohort 6 By Olalekan…
iFrame is not supported! Mezigdomnide Preliminary Results Multiple Myeloma from the Dose-Expansion Phase of the CC-92480-MM-001 By Paul Richardson, MD…
Axicabtagene Ciloleucel (Axi-Cel) Large B-Cell Lymphoma (R/R LBCL): 2-Year Follow-up of ZUMA-1 Cohort 6 By Olalekan Oluwole, MD, MPH, MBBS…
iFrame is not supported! Daratumumab: COVID-19 Impact – Robert Rifkin – ASH 2022 By Robert Rifkin, MD What is the…
Daratumumab: COVID-19 Impact – Robert Rifkin – ASH 2022 By Robert Rifkin, MD What is the Connect® MM Registry and…
iFrame is not supported! Clonal Hematopoiesis: Myeloid Malignancy Prediction – ASH 2022 By LaChelle Weeks, MD, PhD What is clonal…
Clonal Hematopoiesis: Myeloid Malignancy Prediction – ASH 2022 By LaChelle Weeks, MD, PhD What is clonal hematopoiesis and why is…
A new maintenance option is available for AML, but are you proficient in identifying eligible patients? Dr. DiNardo and Dr.…
So, I presented the interim analysis of the second part of the FLARE trial, which is a randomized phase 3…